Company / Cost of Revenue
Veracyte, Inc. Cost of Revenue History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$36.1M
FY2019
5-year range
-
FY2016-FY2019
Trend
+9.1%
vs FY2018
Sector context
#108 of 113
Health Care
What the data says
Among 113 Health Care companies, Veracyte, Inc. is in the top 4% for cost of revenue. Cost of Revenue has increased for 3 consecutive years, from $17M in FY2016 to $36M in FY2019.
Based on SEC 10-K filings.
$36M in FY2019 with a 3-year CAGR of +29.5%.
Increased from $21M to $36M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +29.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 113This company $36.1M Sector average $11.3B
▼
-99.7% below sector average
Key checks
Key Insights
- Veracyte, Inc.'s cost of revenue has grown for 3 consecutive years.
- 3-year CAGR of +29.5%, indicating consistent growth.
- In FY2019, cost of revenue increased 9.1% year-over-year.
- Ranks #108 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $36.1M | +9.1% |
| FY2018 | $33.1M | +53.9% |
| FY2017 | $21.5M | +29.5% |
| FY2016 | $16.6M | -22.8% |
As of FY2019 · SEC 10-K · Updated Jun 30, 2026